Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings

@inproceedings{Lee2012ReviewOT,
  title={Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings},
  author={Janice Soo Fern Lee and Alexandra Calmy and Isabelle Andrieux-Meyer and Nathan Ford},
  booktitle={HIV/AIDS},
  year={2012}
}
Integrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to be a promising once-daily agent when combined with other antiretroviral drugs. Elvitegravir has demonstrated good efficacy and safety, with minimal side effects and no specific requirements in terms of laboratory monitoring. In addition, elvitegravir is available as a fixed-dose combination. However, the drug… CONTINUE READING